8-K: Profound Medical Reports Record Q4 Revenue, Expands Global Reach

Profound Medical Corp. announced record fourth-quarter and full-year 2025 financial results, driven by strong TULSA-PRO sales and strategic global expansion.

Summary

• Fourth quarter 2025 revenue reached a record $6.0 million, a 43% year-over-year increase and 13% sequential growth.
• Full year 2025 revenue was approximately $16.1 million, up from $10.7 million in 2024.
• The TULSA-PRO installed base grew to 78 systems as of December 31, 2025, with an expectation to reach approximately 120 installs by the end of 2026.
• The qualified TULSA-PRO sales pipeline currently stands at 110 new systems.
• Profound strengthened its balance sheet by closing a $36.0 million registered direct offering in the U.S. and an upsized $6.45 million private placement in Canada in December 2025.
• The company launched its TULSA-AI Volume Reduction module, which is expected to streamline workflow, reduce procedure times for BPH, and potentially triple the total available market to about 600,000 patients annually.
• Strategic distribution agreements were established in Saudi Arabia (with Al Faisaliah Medical Systems Co.) and Australia/New Zealand (with Getz Healthcare), and exclusive distribution rights for TULSA-PRO in Canada were regained.
• Key clinical milestones included the Busch Center completing 500 TULSA Procedures and the Hong Center Scottsdale performing 200 TULSA Procedures independently by a urologist.
• The Johns Hopkins Hospital and Mount Sinai Hospital successfully launched TULSA-PRO, treating their first non-clinical-trial prostate cancer patients.
• Profound received the 2025/2026 Mount Logan Award for significant milestones, including treating the 4,000th TULSA Procedure patient and securing U.S. CMS reimbursement at Urology APC Level 7.
• Net loss for Q4 2025 was $8.2 million ($0.27 per share), compared to $4.9 million ($0.20 per share) in Q4 2024.
• Net loss for full year 2025 was $42.6 million ($1.41 per share), compared to $27.8 million ($1.12 per share) in 2024.
• Kris Shah resigned from the Board of Directors, and Frank Baylis was appointed as his successor, effective immediately.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, despite increased losses, due to strong revenue growth, significant market expansion, a robust sales pipeline, and a substantial capital raise that bolsters liquidity for future growth initiatives.

Positives

• Record Q4 2025 revenue of $6.0 million, representing 43% year-over-year and 13% sequential growth.
• Full year 2025 revenue increased to $16.1 million from $10.7 million in 2024.
• TULSA-PRO installed base grew to 78 systems by year-end 2025, with a strong forecast to reach approximately 120 installs by the end of 2026.
• Robust TULSA-PRO qualified sales pipeline of 110 new systems.
• Significant strengthening of the balance sheet with a $36.0 million registered direct offering and a $6.45 million private placement in December 2025, without warrant coverage.
• Launch of TULSA-AI Volume Reduction module expected to increase adoption and triple the total available market for BPH treatment to 600,000 patients annually.
• Expansion into new international markets through strategic distribution agreements in Saudi Arabia, Australia, and New Zealand, and regaining Canadian distribution rights.
• Achievement of significant clinical milestones, including 500 TULSA Procedures at the Busch Center and 200 independent urologist-led TULSA Procedures at the Hong Center Scottsdale.
• Successful commercial launches at prestigious U.S. institutions like Johns Hopkins Hospital and Mount Sinai Hospital.
• Recognition with the 2025/2026 Mount Logan Award for milestones including 4,000 TULSA Procedures and U.S. CMS reimbursement at Urology APC Level 7.
• Full year 2025 gross margin improved to 71% from 66% in 2024, driven by increased selling prices and capital system sales.

Negatives

• Net loss for Q4 2025 increased to $8.2 million ($0.27 per share) from $4.9 million ($0.20 per share) in Q4 2024.
• Net loss for full year 2025 significantly increased to $42.6 million ($1.41 per share) from $27.8 million ($1.12 per share) in 2024.
• Q4 2025 gross margin decreased to 67% from 71% in the prior year period, primarily due to product mix and new market introductory prices with international distributors.
• Total operating expenses for full year 2025 increased substantially to $52.6 million from $40.1 million in 2024, driven by increased headcount, CAPTAIN trial costs, sales force expansion, and infrastructure.

Risks

• Risks inherent in the medical device industry.
• Uncertainties regarding regulatory approvals for products and procedures.
• Challenges related to reimbursement policies and coverage.
• Impact of general economic factors on business operations and market demand.
• Volatility and risks associated with the equity markets.
• Risks associated with company growth and competitive pressures in the market.

Future Outlook

Profound Medical expects to drive high double-digit to low triple-digit revenue growth and ultimately achieve positive cash flows and net profitability. The company anticipates reaching approximately 120 TULSA-PRO installs by the end of 2026, supported by a strong capital sales pipeline and upcoming catalysts, including clinical outcomes from the Level 1 post-market CAPTAIN study.

Management Comments

• "We continued to execute well, delivering record revenues, an expanded TULSA-PRO installed base, and a stronger capital sales pipeline again in the fourth quarter validating our belief that Q3-2025 marked an important inflection point in our business."
• "Moving forward, with the strengthening of our balance sheet via the completion of our financing in December, and based on several upcoming potential catalysts, including the clinical outcomes from the Level 1 post-market CAPTAIN study, we believe that we are on the right path toward driving high double digit to low triple digit revenue growth and, ultimately, positive cash flows and net profitability."

Industry Context

StockSavvy.ai notes that Profound Medical's strong revenue growth and expanding installed base for TULSA-PRO position it well within the competitive interventional MRI (iMRI) and prostate therapy market. The introduction of the TULSA-AI Volume Reduction module aligns with the broader industry trend of integrating artificial intelligence to enhance procedural efficiency and expand market reach for medical devices. Strategic partnerships and global expansion efforts are crucial for capturing market share in a rapidly evolving healthcare technology landscape, especially as demand for less invasive prostate treatments grows.

Comparison to Industry Standards

• The TULSA-PRO system's ability to treat a wide variety of prostate disease patients (67% prostate cancer only, 17% hybrid, 13% salvage, 3% BPH only) demonstrates versatility that may exceed single-indication devices from competitors.
• The achievement of 200 TULSA Procedures performed independently by a urologist at the Hong Center Scottsdale highlights a significant step towards broader adoption and reduced reliance on radiologists, potentially streamlining workflow compared to other MRI-guided procedures that require more specialized imaging expertise.
• Securing reimbursement for the TULSA Procedure by the U.S. Centers for Medicare & Medicaid Services (CMS) at Urology APC Level 7 is a critical benchmark, indicating a favorable position for market access and adoption compared to novel therapies still awaiting such coverage.
• The expected expansion of the TULSA-PRO installed base to approximately 120 systems by the end of 2026, from 78 at year-end 2025, suggests a growth trajectory that is competitive within the high-capital medical device sector, where significant upfront investment is required from healthcare providers.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value through revenue growth, market expansion, and future profitability, but diluted by recent capital raise and current increased net losses.
• Employees: Increased headcount and sales force expansion indicate growth opportunities and job security.
• Customers (Hospitals/Clinics): Enhanced treatment options with TULSA-PRO and Sonalleve, including the new TULSA-AI module, offering improved efficiency and patient outcomes.
• Patients: Expanded access to advanced, incision-free prostate therapies (TULSA Procedure) and other MRI-guided treatments (Sonalleve) through new installations and distribution agreements.
• Creditors: Strengthened balance sheet with a significant capital raise improves the company's financial stability and ability to meet obligations.

Next Steps

• Presentation of the first clinical outcomes from the Level 1 post-market CAPTAIN trial at the 41st Annual European Association of Urology (EAU) Congress in London, UK, on March 13, 2026.
• Continued execution of the commercialization strategy for TULSA-PRO and Sonalleve globally.
• Expansion of the TULSA-PRO installed base to approximately 120 systems by the end of 2026.
• Driving high double-digit to low triple-digit revenue growth.
• Working towards achieving positive cash flows and net profitability.

Key Dates

Recommendation

While Profound Medical demonstrates strong revenue growth, significant market expansion, and a bolstered balance sheet, the substantial increase in net losses and operating expenses indicates continued heavy investment in growth. The upcoming CAPTAIN trial results are a key catalyst, but until there is clearer evidence of a path to profitability and sustained gross margin improvement, a 'hold' recommendation is prudent for a seasoned investor. The company is executing on its strategy, but the financial performance still reflects a growth-stage company with associated risks.

Keywords

Profound Medical, TULSA-PRO, Sonalleve, MRI-guided therapy, Prostate cancer, Benign prostatic hyperplasia, BPH, Medical device, Interventional MRI, iMRI, Urology, Oncology, Healthcare technology, Financial results, Capital raise, Distribution agreements, CMS reimbursement, AI in healthcare